Viewing Study NCT00105092


Ignite Creation Date: 2025-12-24 @ 3:53 PM
Ignite Modification Date: 2025-12-28 @ 7:06 PM
Study NCT ID: NCT00105092
Status: COMPLETED
Last Update Posted: 2007-05-01
First Post: 2005-03-04
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.
Sponsor: Eli Lilly and Company
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module